TAK-994

DRUG5 trials

Sponsors

Takeda

Conditions

Healthy ParticipantsHealthy VolunteersNarcolepsy Type 1 (NT 1)Narcolepsy Type 1 (NT1)Narcolepsy Type 2 (NT2)

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

CompletedNCT03933488

TakedaHealthy Participants

Start: 2019-05-01End: 2020-03-29Updated: 2020-06-24

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants

CompletedNCT04551079

TakedaHealthy Volunteers

Start: 2020-09-23End: 2020-12-31Updated: 2021-01-19

A Study of Different Forms of TAK-994 in Healthy Adults

CompletedNCT04745767

TakedaHealthy Participants

Start: 2021-02-16End: 2021-04-05Updated: 2021-04-22

Phase 2

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

TerminatedNCT04096560

TakedaNarcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)

Start: 2020-05-27End: 2021-11-05Updated: 2024-10-29

A Study of TAK-994 in Adults With Narcolepsy

TerminatedNCT04820842

TakedaNarcolepsy Type 1 (NT 1)

Start: 2021-04-30End: 2021-11-03Updated: 2023-12-26

Related Papers

Functional Regression Methods for Estimating 24-hour Ambulatory Blood Pressure and Heart Rate Parameters in Narcolepsy Type 1

Digital Biomarkers2026-03-03

0674 The Functional Impacts of Narcolepsy Instrument Differentiates Patients with Narcolepsy from Healthy Controls

SLEEP2024-04-20

Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1

New England Journal of Medicine2023-07-2675 citations

Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials

CNS Drugs2021-12-2113 citations